Type 2 diabetes associated with increased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Diabetes Care, researchers from the Utrecht University Institute of Pharmaceutical Sciences in Utrecht, the Netherlands, have found that type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
For the study, researchers sought to investigate the risk of colorectal cancer in patients with type 2 diabetes and to assess whether treatment stage and duration of obesity affect that risk.
They identified 2,759 patients with type 2 diabetes and colorectal cancer after a median follow-up of 4.5 years from the Clinical Practice Research Datalink. All patients were on at least one prescription drug for type 2 diabetes. Results showed that type 2 diabetes was linked with a 1.3-fold increased risk for developing colorectal cancer (HR = 1.26; 95% CI: 1.18 - 1.33).
There was no association between treatment stages and colorectal cancer risk, but patients with obesity for 4 to 8 years (HR = 1.19; 95% CI: 1.06 - 1.34) and those with obesity for more than 8 years (HR = 1.28; 95% CI: 1.11 - 1.49) had a significantly increased risk of colorectal cancer.
The findings suggest that patients with type 2 diabetes, especially those who have been obese for 4 or more years, have an increased risk for developing colorectal cancer.
Type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|